Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Rapid Micro Biosystems (RPID) Cost of Revenue (2020 - 2025)

Rapid Micro Biosystems' Cost of Revenue history spans 6 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Cost of Revenue fell 14.25% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $11.7 million, down 12.67%, while the annual FY2024 figure was $13.3 million, 0.42% changed from the prior year.
  • Cost of Revenue for Q3 2025 was $2.9 million at Rapid Micro Biosystems, down from $3.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $4.1 million in Q4 2022 and bottomed at $2.3 million in Q1 2021.
  • The 5-year median for Cost of Revenue is $3.3 million (2024), against an average of $3.3 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 152.59% in 2021 before it decreased 23.35% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $3.4 million in 2021, then increased by 22.92% to $4.1 million in 2022, then fell by 23.35% to $3.2 million in 2023, then fell by 5.66% to $3.0 million in 2024, then dropped by 2.92% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Cost of Revenue are $2.9 million (Q3 2025), $3.1 million (Q2 2025), and $2.8 million (Q1 2025).